I domain chimeric antigen receptor specific to ICAM-1
The present invention relates to chimeric antigen receptors (CARs) specific to ICAM-1 comprising I domain of the α L subunit of human lymphocyte function-associated antigen 1 (LFA-1). The invention particularly relates to CARs comprising human I domains having different affinities (1 mM to 1 nM Kd) to ICAM-1. CAR T cells comprising human I domain having a low affinity (1 to 200 μM Kd) to ICAM-1 can avoid targeting healthy tissues with basal ICAM-1 expression while simultaneously exhibiting increased potency and long-term efficacy against tumor tissues with high ICAM-1 expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human I domain to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing ICAM-1 and kill the cancer cells.
1. A Chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus:
(i) an I domain of the α L subunit of human lymphocyte function-associated antigen-1,
(ii) a transmembrane domain,
(iii) at least one co-stimulatory domains, and
(iv) an activating domain, wherein the I domain binds ICAM-1 at an affinity between about 145 nM to about 20 μM, and the I domain comprises the sequence of 130-310 amino acids of SEQ ID NO: 1, with one mutation of F292A, F292S, L289G, or F265S.
2. The CAR according to claim 1 , wherein the co-stimulatory domain is selected from the group consisting of CD28, 4-1BB, ICOS-1, CD27, OX-40, GITR, and DAP10.
3. The CAR according to claim 1 , wherein the activating domain is CD3 zeta.
4. An isolated nucleic acid encoding the CAR of claim 1 .
5. T cells or natural killer cells modified to express the CAR of claim 1 .
6. An adoptive cell therapy method for treating cancer, comprising the steps of:
obtaining CAR-T cells expressing a chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus:
(i) an I domain of the α L subunit of human lymphocyte function-associated antigen-1,
(ii) a transmembrane domain,
(iii) at least one co-stimulatory domains, and
(iv) an activating domain, wherein the I domain binds ICAM-1 at an affinity between about 145 nm to about 20 μM, and the I domain comprises the sequence of 130-310 amino acids of SEQ ID NO: 1, with one mutation of F292A, F292S, L289G, or F265S,
administering the CAR-T cells to a subject suffering from cancer, wherein the cancer cells of the subject overexpress ICAM-1, and the CAR T cells bind to the cancer cells to kill the cancer cells.
7. The method according to claim 6 , wherein the cancer is thyroid cancer, gastric cancer, pancreatic cancer, or breast cancer.
8. The method according to claim 6 , wherein the one mutation is F292A.
9. The method according to claim 6 , wherein the co-stimulatory domain is selected from the group consisting of CD28, 4-1BB, ICOS-1, CD27, OX-40, GITR, and DAP10.
10. The method according to claim 6 , wherein the co-stimulatory domain comprises CD28 and 4-1BB.
11. The CAR according to claim 6 , wherein the activating domain is CD3 zeta.
12. The CAR according to claim 1 , wherein the one mutation is F292A.
13. The CAR according to claim 1 , wherein the co-stimulatory domain comprises CD28 and 4-1BB.